본문 바로가기
KERD
논문KCI 등재

Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals

이창섭|Kim Min-Kyung|Park Jun-Sun|Jeon Jaehyun|Um Jihye|Choi Youn Young|Lee Kyung-Shin|Sung Ho Kyung|Jang Hee-Chang|Chin BumSik|Kim Choon Kwan|Oh Myung-don
대한감염학회 (The Korean Society Of Infectious Diseases)|2024.03|Infection and Chemotherapy|제56권 제1호|pp. 25-36|DOI 10.3947/ic.2023.0057

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

AntibodiesHumoral immunityCOVID-19 vaccine third doseNeutralizingSARS-CoV-2 Omicron variant
주제분류내과학

초록

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) is dominating coronavirus disease 2019 (COVID-19) worldwide. The waning protective effect of available vaccines against the Omicron variant is a critical public health issue. This study aimed to assess the impact of the third COVID-19 vaccination on immunity against the SARS-CoV-2 Omicron BA.1 strain in older individuals. Materials and Methods Adults aged ≥60 years who had completed two doses of the homologous COVID-19 vaccine with either BNT162b2 (Pfizer/BioNTech, New York, NY, USA, BNT) or ChAdOx1 nCoV (SK bioscience, Andong-si, Gyeongsangbuk-do, Korea, ChAd) were registered to receive the third vaccination. Participants chose either BNT or mRNA-1273 (Moderna, Norwood, MA, USA, m1273) mRNA vaccine for the third dose and were categorized into four groups: ChAd/ChAd/BNT, ChAd/ChAd/m1273, BNT/BNT/BNT, and BNT/BNT/m1273. Four serum specimens were obtained from each participant at 0, 4, 12, and 24 weeks after the third dose (V1, V2, V3, and V4, respectively). Serum-neutralizing antibody (NAb) activity against BetaCoV/Korea/KCDC03/2020 (NCCP43326, ancestral strain) and B.1.1.529 (NCCP43411, Omicron BA.1 variant) was measured using plaque reduction neutralization tests. A 50% neutralizing dilution (ND50) >10 was considered indicative of protective NAb titers. Results In total, 186 participants were enrolled between November 24, 2021, and June 30, 2022. The respective groups received the third dose at a median (interquartile range [IQR]) of 132 (125 - 191), 123 (122 - 126), 186 (166 - 193), and 182 (175 - 198) days after the second dose. Overall, ND50 was lower at V1 against Omicron BA.1 than against the ancestral strain. NAb titers against the ancestral strain and Omicron BA.1 variant at V2 were increased at least 30-fold (median [IQR], 1235.35 [1021.45 - 2374.65)] and 129.8 [65.3 - 250.7], respectively). ND50 titers against the ancestral strain and Omicron variant did not differ significantly among the four groups (P = 0.57). NAb titers were significantly lower against the Omicron variant than against the ancestral strain at V3 (median [IQR], 36.4 (17.55 - 75.09) vs. 325.9 [276.07 - 686.97]; P = 0.012). NAb titers against Omicron at V4 were 16 times lower than that at V3. Most sera exhibited a protective level (ND50 >10) at V4 (75.0% [24/32], 73.0% [27/37], 73.3% [22/30], and 70.6% [12/17] in the ChAd/ChAd/BNT, ChAd/ChAd/m1273, BNT/BNT/BNT, and BNT/BNT/m1273 groups, respectively), with no significant differences among groups (P = 0.99). Conclusion A third COVID-19 mRNA vaccine dose restored waning NAb titers against Omicron BA.1. Our findings support a third-dose vaccination program to prevent the waning of humoral immunity to SARS-CoV-2.

Abstract

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) is dominating coronavirus disease 2019 (COVID-19) worldwide. The waning protective effect of available vaccines against the Omicron variant is a critical public health issue. This study aimed to assess the impact of the third COVID-19 vaccination on immunity against the SARS-CoV-2 Omicron BA.1 strain in older individuals. Materials and Methods Adults aged ≥60 years who had completed two doses of the homologous COVID-19 vaccine with either BNT162b2 (Pfizer/BioNTech, New York, NY, USA, BNT) or ChAdOx1 nCoV (SK bioscience, Andong-si, Gyeongsangbuk-do, Korea, ChAd) were registered to receive the third vaccination. Participants chose either BNT or mRNA-1273 (Moderna, Norwood, MA, USA, m1273) mRNA vaccine for the third dose and were categorized into four groups: ChAd/ChAd/BNT, ChAd/ChAd/m1273, BNT/BNT/BNT, and BNT/BNT/m1273. Four serum specimens were obtained from each participant at 0, 4, 12, and 24 weeks after the third dose (V1, V2, V3, and V4, respectively). Serum-neutralizing antibody (NAb) activity against BetaCoV/Korea/KCDC03/2020 (NCCP43326, ancestral strain) and B.1.1.529 (NCCP43411, Omicron BA.1 variant) was measured using plaque reduction neutralization tests. A 50% neutralizing dilution (ND50) >10 was considered indicative of protective NAb titers. Results In total, 186 participants were enrolled between November 24, 2021, and June 30, 2022. The respective groups received the third dose at a median (interquartile range [IQR]) of 132 (125 - 191), 123 (122 - 126), 186 (166 - 193), and 182 (175 - 198) days after the second dose. Overall, ND50 was lower at V1 against Omicron BA.1 than against the ancestral strain. NAb titers against the ancestral strain and Omicron BA.1 variant at V2 were increased at least 30-fold (median [IQR], 1235.35 [1021.45 - 2374.65)] and 129.8 [65.3 - 250.7], respectively). ND50 titers against the ancestral strain and Omicron variant did not differ significantly among the four groups (P = 0.57). NAb titers were significantly lower against the Omicron variant than against the ancestral strain at V3 (median [IQR], 36.4 (17.55 - 75.09) vs. 325.9 [276.07 - 686.97]; P = 0.012). NAb titers against Omicron at V4 were 16 times lower than that at V3. Most sera exhibited a protective level (ND50 >10) at V4 (75.0% [24/32], 73.0% [27/37], 73.3% [22/30], and 70.6% [12/17] in the ChAd/ChAd/BNT, ChAd/ChAd/m1273, BNT/BNT/BNT, and BNT/BNT/m1273 groups, respectively), with no significant differences among groups (P = 0.99). Conclusion A third COVID-19 mRNA vaccine dose restored waning NAb titers against Omicron BA.1. Our findings support a third-dose vaccination program to prevent the waning of humoral immunity to SARS-CoV-2.

참고문헌 (39)

  1. "Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern"[URL]
  2. Pulliam JRC, "Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa", Science, 376, pp.eabn4947~ (2022)
  4. Liu C, "Reduced neutralization of SARS-CoV-2 B. 1. 617 by vaccine and convalescent serum", Cell, 184, pp.4220~4236 (2021)
  5. Bartleson JM, "SARS-CoV-2, COVID-19 and the ageing immune system", Nat Aging, 1, pp.769~782 (2021)
  6. Cunningham AL, "Vaccines for older adults", BMJ, 372, pp.n188~ (2021)
  7. "Coronavirus disease-19, Republic of Korea"[URL]
  8. "Intensive implementation of COVID-19 booster vaccination in nursing homes"[URL]
  9. Nham E, "COVID-19 Vaccination in Korea : past, present, and the way forward", J Korean Med Sci, 37, pp.e351~ (2022)
  10. Kim J, "Effectiveness of booster mRNA vaccines against SARS-CoV-2 infection in an elderly population, South Korea, October 2021-January 2022", Clin Infect Dis, 75, pp.920~921 (2022)
  11. Accorsi EK, "Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants", JAMA, 327, pp.639~651 (2022)
  12. Barda N, "Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel : an observational study", Lancet, 398, pp.2093~2100 (2021)
  13. Bruxvoort KJ, "Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2 : test negative case-control study", BMJ, 375, pp.e068848~ (2021)
  14. Canetti M, "Six-month follow-up after a fourth BNT162b2 vaccine dose", N Engl J Med, 387, pp.2092~2094 (2022)
  15. Collie S, "Effectiveness and durability of the BNT162b2 vaccine against Omicron sublineages in South Africa", N Engl J Med, 387, pp.1332~1333 (2022)
  16. Westhaus S, "Neutralization assay for SARS-CoV-2 infection : plaque reduction neutralization test", Methods Mol Biol, 2452, pp.353~360 (2022)
  17. Follmann D, "Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial", Ann Intern Med, 175, pp.1258~1265 (2022)
  18. Assis R, "Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination", NPJ Vaccines, 6, pp.132~ (2021)
  19. [URL]
  20. GeurtsvanKessel CHGeers D, "Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients", Sci Immunol, 7, pp.eabo2202~ (2022)
  21. Khoury DS, "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection", Nat Med, 27, pp.1205~1211 (2021)
  23. Lopez Bernal J, "Effectiveness of Covid-19 vaccines against the B. 1. 617. 2(Delta)Variant", N Engl J Med, 385, pp.585~594 (2021)
  24. Shao W, "Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world : a literature review and meta-analysis", Emerg Microbes Infect, 11, pp.2383~2392 (2022)
  25. Hoffmann M, "The Omicron variant is highly resistant against antibody-mediated neutralization : implications for control of the COVID-19 pandemic", Cell, 185, pp.447~456 (2022)
  26. Bergwerk M, "Covid-19 breakthrough infections in vaccinated health care workers", N Engl J Med, 385, pp.1474~1484 (2021)
  27. Andrews N, "Covid-19 vaccine effectiveness against the Omicron(B. 1. 1. 529)variant", N Engl J Med, 386, pp.1532~1546 (2022)
  28. Gruell H, "mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant", Nat Med, 28, pp.477~480 (2022)
  29. Earle KA, "Evidence for antibody as a protective correlate for COVID-19 vaccines", Vaccine, 39, pp.4423~4428 (2021)
  30. "Recommendations for investigational COVID-19 convalescent plasma" (2022)[URL]
  31. Lee WT, "Neutralizing antibody responses in COVID-19 convalescent sera", J Infect Dis, 223, pp.47~55 (2021)
  32. Roeder AJ, "Longitudinal comparison of neutralizing antibody responses to COVID-19 mRNA vaccines after second and third doses", Vaccines(Basel), 10, pp.1459~ (2022)
  33. Robbiani DF, "Convergent antibody responses to SARS-CoV-2 in convalescent individuals", Nature, 584, pp.437~442 (2020)
  35. Planas D, "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization", Nature, 602, pp.671~675 (2022)
  36. Garcia-Beltran WF, "mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant", Cell, 185, pp.457~466 (2022)
  37. Müller L, "Age-dependent immune response to the Biontech", Pfizer BNT162b2 coronavirus disease 2019 vaccination, 2021, pp.73, 2065~2072
  38. Romero-Olmedo AJ, "Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults", Nat Microbiol, 7, pp.195~199 (2022)
  39. Newman J, "Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2", Nat Microbiol, 7, pp.1180~1188 (2022)

관련 논문AI추천

Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine노지윤, 송준영, Cheong Hee Jin, Choi Jaeuk, Hwang Soon Young, Kim Jeonghun, Kim Jineui, Kim Kyung Taek, Kim Woo Joo, Lee Jungmin, Lee Sohyun, Nham Eliel, Park Heedo, Park Man-Seong, Yoon Jin Gu대한면역학회 · Immune Network2023 · 제23권 제6호Immunogenicity of Third-dose BNT162b2 mRNA Vaccine Following Two Doses of ChAdOx1 in Health Care Workers: A Prospective Longitudinal Study신정원, Bang Hae In, Choi Tae Youn, Jang Eui Young, Kim Jieun, Kim Jung-Ah, Kim Mi-Young, Kim Saerom, Park Rojin, Park Yoonhye, Shin Woo Yong대한진단검사의학회 · Annals of Laboratory Medicine2022 · 제42권 제6호Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare WorkersKim Dong Wan, Lee Jung Young, Lee Yuil, Lim Sera, Park Won Sang, Yoon Jung Hwan대한감염학회 · Infection and Chemotherapy2022 · 제54권 제1호Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in KoreaChoi Eun Bee, Do Hyeon Nam, In Hyun Ju, Jang Sundong, Kim Byoungguk, Kim Byung Chul, Kim Kwangwook, Kim Soo Ji, Lee June-Woo, Lee Yoo-kyoung, Lim Heeji, Lim Hye Jung, Ouh In-ohk, Yim Min Su대한감염학회 · Infection and Chemotherapy2023 · 제55권 제1호Neutralization Testing–based Immunogenicity Analysis of Recent Prevalent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron SublineagesChoi Young-Ki, Kim Dong Ju, Kim Eun-Jin, Kim Il-Hwan, Kim Jeong-Ah, Kim Jeong-Min, Lee Chae Young, Lee Eun Ju, Lee Hyeokjin, No Jin Sun, O Sang Won, Park Ae Kyung, Rhee Jee Eun대한진단검사의학회 · Annals of Laboratory Medicine2024 · 제44권 제3호Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19권기태, 김신우, 김윤정, 박만성, 배소현, 배준용, 이원기, 이지은, 장현하, 황소윤, Chunguang Cui연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제7호

이 간행물의 다른 논문 (16건)

Epidemiology and Disease Burden of Respiratory Syncytial Virus Infection in Adults최상호, Kim Taeeunpp. 1-12Identification and Antimicrobial Susceptibilities for Patients with Non-tuberculous Mycobacteria Infection in Jeju Island: Single-Center Retrospective Study이종후, Kim Misun, Kim Miok, Kim Changhwan, Seong Gil Myeong, Kang Myeong Jin, Yoo Jeong Rae, 이재천, 허상택pp. 13-24Comparative Effects of Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines in The Prevention of Genotype-Specific Infection: A Systematic Review and Network Meta-AnalysisOh Jin-Kyoung, Choe Young June, Kim Jimin, Park Jungeun, Yu Su-Yeon, Shim Eunha, Park Mihai, Cho Jahyun, Cheong Chelimpp. 37-46No Significant Differences in Presepsin Levels According to the Causative Microorganism of Bloodstream InfectionLee Beomki, 이남용, 신태건, Park Jong Eun, Yoon Sun Joo, Park Chi-Min, 강은숙pp. 47-56Phage Therapy in Korea: A Prescribers' Survey of Attitudes Amongst Korean Infectious Diseases Specialists Towards Phage TherapyLee Shinwon, Iredell Jonathan R, Myung Heejoon, Lin Ruby C Y, Lynch Stephaniepp. 57-65
원문 보기